Search

The wide availability, speed, safety, and diagnostic accuracy of multidetector computed tomography (MDCT) make it the first-line diagnostic tool in the study of acute bleeding of the lower digestive tract. The use of MDCT after the initial stabilization of the patient makes it possible to identify active bleeding and to determine its origin and possible cause, even when bleeding has stopped. MDCT provides information that is key to selecting the most appropriate treatment option: colonoscopy, embolization, surgery, or clinical follow-up. MDCT orients the surgical or endovascular intervention, minimizing the time, risks, and doses of radiation and of contrast agents involved in the intervention and avoiding "blind" resections associated with greater morbimortality. Although the active presence of radiologists in the Emergency Department involves some disadvantages in scheduling, it also places radiologists in a privileged position in their relations with other techniques and professionals involved in the management of acute lower digestive tract bleeding., (Copyright © 2010 SERAM. Published by Elsevier Espana. All rights reserved.)

INTRODUCTION. The main goal of this work was to identify subgroups of patients with fibromyalgia (FM) by means of a frequently used clinical tool, the Fibromyalgia Impact Questionnaire (FIQ). METHODOLOGY. A total of 66 women diagnosed with FM participated in the study. Two subgroups of patients were identified by analysis of a hierarchical cluster of selected items from the FIQ (pain, fatigue, morning tiredness, stiffness, anxiety and depressive symptoms). RESULTS. The type I FM-group had very high levels of fatigue, morning tiredness and anxiety, and high levels of joint stiffness, pain and depressive symptoms, while the type II FM-group had predominantly moderate levels of fatigue and morning tiredness, with moderate low levels of pain and stiffness along with a low level of depression and anxiety. CONCLUSIONS. Type I FM-group also had lower healthrelated quality of life, especially through emotional reactions and social isolation as well as more psychopathological affections than presented by type II FM-group.

The goals of this study are the preliminary Spanish adaptation and validation of the following questionnaires: the Children's Eating Attitudes Test (ChEAT), the Lawrence Self-Esteem Questionnaire (LAWSEQ) and the Body Esteem Scale (BES). In addition, we studied bodily self-esteem in pre-adolescent children, and their possible relation to certain eating attitudes and general self-esteem. This study is cross-sectional, analytical and observational. The sample was made up of 457 participants, 55.14% boys and 44.86% girls aged between 8 and 12 (M = 10.14, SD = 1.30). A multivariate analysis of variance (Age x Sex) was carried out with the total scores of LAWSEQ, ChEAT, BES, BIA and BMI. Cronbach's alpha reliability coefficient was .76, .80, and .67 for ChEAT, BES, and LAWSEQ, respectively. The boys presented significantly higher total scores in the ChEAT than the girls. Of the sample, 10.4% (n = 45) scored over the cut-off point of the ChEAT: These subjects presented lower general and bodily self-esteem, a slimmer ideal image and a greater discrepancy between their real self and their social self.

Chronic inflammatory diseases and infections are a major cause of hyporesponse to erythropoiesis-stimulating factors. We conducted this prospective study in 107 patients in haemodialysis with dialysis liquid that was potentially contaminated from a bacteriological perspective in order to test the hypothesis that ultrapure dialysis liquid can improve the response to treatment with darbepoetin and reduce inflammatory markers. These patients had to have been stable in the last 8 weeks in relation to haemoglobin level and the administered dose of darbepoetin. Two filters (one of hydrophilic nylon and another of polysulfone) were added to the water treatment process, the first one prior to distribution ring output and the second before the dialyser. The patients were evaluated for 12 months. The dosage of darbepoetin was varied to maintain haemoglobin levels ranging from 11 to 14 g/dl. We measured resistance to the erythropoiesis-stimulating factor, defined as the quotient between weekly dose of darbepoetin and haemoglobin levels, baseline and every two months, the baseline and monthly endotoxin count and reactive protein C at baseline and every 6 months. 94 patients completed the study. The resistance index fell significantly during follow-up (p<0.001) and was measurable from the second month on. Haemoglobin levels remained within the established margins with a 34% reduction in the weekly dose of darbepoetin at the end of the follow-up period. Both reactive protein C and the endotoxin count were significantly reduced (p<0.001) compared to baseline after 6 and 12 months. To conclude, the bacteriological purity of the dialysis liquid reduces inflammatory markers in patients receiving haemodialysis, improving the response to treatment with darbepoetin in renal anaemia.

A bilioma is an encapsulated collection of bile outside the biliary tree, which, in general, appears after a laceration in the biliary tract secondary to traumatism or to an iatrogenic lesion. Rarely, it occurs without a traumatic factor. We present two cases of bilioma as a complication of acute alithiasic cholecystitis. A review of the literature and the role of the ultrasonography in the diagnosis and management of biliomas is performed.

This randomized, prospective, two-arm clinical study evaluated the antiproteinuric and nephroprotective effects and the safety of treatment with an angiotensin II receptor antagonist (irbesartan) in patients with chronic glomerulonephritis (CGN) as compared to angiotensin-converting enzyme inhibitors (ACEIls). A total of 50 patients with CGN diagnosed by renal biopsy and protein levels in 24-hour urine higher than 1 g were enrolled. All patients received treatment for at least 24 months, 27 in group 1 (irbesartan) and 23 in group 2 (ACEs). A significant decrease in proteinuria (p < 0.001) was seen in both groups (49.2% in group, 1, and 44.8% in group 2) since the third month, and confirmed at 12 and 24 months of follow-up (58.1% and 62.7% in group 1, and 56.8% and 55.4% in group 2, respectively), with no significant differences being seen between the two groups. No differences were found in blood pressure control. No significant decrease was found in any of the groups in the glomerular filtration rate, but this showed higher values in the group treated with ACEIs (2.98 +/- 7.77 vs 1.64 +/- 6.84 ml/min/year), though the difference with irbersartan was not statistically significant. No side effects occurred among patients treated with irbesartan, whereas three patients initially treated with ACEIs showed intolerance (cough). In conclusion, irbesartan showed in our study an antiproteinuric and nephroprotective effect similar to ACEIs in patients with chronic glomerulonephritis, and its administration was also shown to be safe.

Darbepoetin alfa is an erythropoiesis-stimulating glycoprotein with up to 3 times longer half-life than recombinant human erythropoietin (rHuEPO) in humans. The aim of this study was to assess the efficacy and safety of darbepoetin alfa given once every other week as treatment of anemia in predialysis patients with chronic renal failure (CRF) previously treated with once-weekly epoetin alfa. A total of 42 CRF patients were included, all of whom had previously been treated with epoetin alfa and showed stable hemoglobin (Hb) levels without dose changes during the last 8 weeks prior to enrolment in this study. All patients received s.c. darbepoetin alfa once every other week at doses calculated from the protein mass equivalence between rHuEPO and darbepoetin alfa. Follow-up lasted for 24 weeks. Dose adjustments were conducted to preserve target Hb levels between 11 and 13 g/dl. Thirty-nine patients completed the 24 weeks of study. Hb levels increased during follow-up [mean values of 0.39 (p < 0.002), 0.58) (p < 0.001), and 0.83 g/dl (p < 0.001) at 8, 16 and 24 weeks, respectively] despite reducing the darbepoetin alfa dose up to 15% at 24 weeks [from 0.192 microg/kg body weight to 0.185, 0.178 and 0.163 at 8, 16, and 24 weeks, respectively (p < 0.001)]. No adverse events related to darbepoetin alfa were reported. In conclusion, these results show s.c. administration of darbepoetin alfa once every other week was superior to weekly epoetin alfa as a maintenance treatment for anemia in predialysis CRF patients, since the former provided higher Hb levels. Moreover, darbepoetin alfa administration was safe in these patients.

This prospective, two-arm, clinical trial assesses the effectiveness in maintaining the levels of haemoglobin (Hb) between 11 and 13 g/d1 and the safety of changing the administration route (from subcutaneous to intravenous) of epoetin (rHuEPO) alpha at equidose versus a changeover to darbepoetin alpha, taking the exact equivalence in peptide mass between the two as referent in patients with chronic renal insufficiency (CRI) in haemodialysis. A total of 112 patients previously treated with epoetin and no dose modification during the 8 weeks prior to the study and stable levels of Hb were included. Of these, 92.1% finished the follow-up period (24 weeks). After changing the administration route of rHuEPO, a significant increase in the resistance index (REI, weekly dose per kilogram of weight/levels of hemoglobin) was observed with mean values of 2.73 (p < 0.018) and 4.37 (p < 0.001) after 16 and 24 weeks respectively, requiring an increase of the dose greater than 15% over the baseline in 6 1.1% of the patients. The changeover to, darbepoetin alpha, independently of the administration route, was accompanied by a decrease in REI starting in the 8th week (mean levels of 0.012, 0.018 and 0.023 after 8, 16 and 24 weeks respectively), significant (p < 0.001) at the 3 cutoff points of the study. The conversion factor increased significantly up to 1:260 in week 24. Both erythropoietic stimulating factors (EST) were well tolerated and no unexpected side effects were observed. In conclusion, treatment of anaemia with darbepoetin alpha in patients with CRI in haemodialysis previously treated with rHuEPO proved to be more effective than the use of epoetin intravenously, significantly improving the resistance index. In addition, the treatment with darbepoetin alpha was well tolerated in these patients.

A descriptive type of study was utilized in the presentation of this paper. The main sources of information were the different government hospitals namely, East Avenue Medical Center, Jose R. Reyes Memorial Hospital, Philippine Orthopedic Hospital, and V. Luna Memorial Hospital. This paper was based on information gathered from actual cases and medical records of the patients treated in the above mentioned government hospitals from July 1995 to July 1996. The results of the study sample shows that 117 (84.8%) males were affected. The major cause of mandibular fracture was alleged assaults or mauling comprising 60 (43.5%) cases of the entire study. The symphysis was the part of the mandible most susceptible to fracture having 75 (54%) cases of the study.

Previously we demonstrated that treatment of mice with either UVB radiation or supernatants derived from UVB-irradiated PAM 212 keratinocytes decreased the induction of the delayed-type hypersensitivity (DTH) response to Mycobacterium bovis bacillus Calmette-Guerin (BCG), impaired the clearance of bacteria from their lymphoid organs and also altered macrophage functions. In order to characterize the cytokines involved in these phenomena, UV-irradiated mice were injected with antibodies to interleukin-10 (IL-10), transforming growth factor-beta 1 (TGF-beta 1), or tumor necrosis factor-alpha (TNF-alpha). Injection of UVB-irradiated mice with anti-IL-10 immediately after UV irradiation restored the DTH response and reversed the UV-induced inhibition of bacterial clearance. Injection of UV-irradiated mice with anti-TGF-beta only partially restored the DTH response although it allowed a better clearance of BCG than injection of mice with the control antibody. In contrast, injection of anti-TNF-alpha did not affect the UVB-induced suppression of DTH or impaired bacterial clearance. Similarly, the ability of macrophages to phagocytose BCG and kill the intracellular organisms was restored to almost normal levels after injecting UV-irradiated mice with antibodies specific for IL-10 or TGF-beta. Injection of mice with either recombinant IL-10 or TGF-beta mimicked the effect of whole-body UV irradiation on immune function. These results suggest that IL-10 has a major role in UV-induced suppression of both DTH to BCG and impairment in the clearance of bacteria and that TGF-beta has a more significant role in blocking bacterial clearance. Furthermore, these cytokines seem to modulate immune responses by altering macrophage functions in UVB-irradiated mice.